Dr. Hahn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637Phone+1 773-702-5381Fax+1 773-702-3163
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007- University of ChicagoResidency, Internal Medicine, 2001 - 2004
Emory University School of MedicineClass of 2001
Certifications & Licensure
IL State Medical License 2004 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2013 Dec 13
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
- Join now to see all
Publications & Presentations
PubMed
- Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.Emily Ly, Frederick M Howard, Nan Chen, Olwen Hahn, Gini F Fleming
Journal of Oncology Pharmacy Practice. 2024-12-09 - Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.Kun Lin, Elena Michaels, Eric Polley, Peter H O'Donnell, Frederick M Howard
Journal of Oncology Pharmacy Practice. 2024-10-13 - 4 citationsAdjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.Andrea B Apolo, Karla V Ballman, Guru Sonpavde, Stephanie Berg, William Y Kim
The New England Journal of Medicine. 2024-09-15
Journal Articles
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
Authored Content
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
- Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018
Press Mentions
Bodybuilder’s Battle with Breast Cancer: “Emotionally I Was a Wreck.”January 27th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
